Stephen George Dilly, President and CEO at Aimmune Therapeutics, Inc. (AIMT), sold 147,692 shares at $26.24 ($3.9M) on 2017-10-05, disclosed to the SEC on 2017-10-06.
Open-market sale of $3.9M AIMT by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.21 | 50,000 | $1.3M | 33.8% |
| 2 | $26.26 | 30,110 | $791K | 20.4% |
| 3 | $26.26 | 30,110 | $791K | 20.4% |
| 4 | $26.24 | 14,689 | $385K | 9.9% |
| 5 | $26.24 | 14,689 | $385K | 9.9% |
| 6 | $26.31 | 4,047 |
| $106K |
| 2.7% |
| 7 | $26.31 | 4,047 | $106K | 2.7% |
| Total | $26.24 avg | 147,692 | $3.9M | 100% |
| Filing → |
| SRRA | BUY | 2021-05-20 | $178K | — | Filing → |
| SGMO | SELL | 2020-03-20 | $210K | — | Filing → |
| SGMO | SELL | 2020-03-18 | $90K | — | Filing → |